IRIDEX : Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe Technology

MOUNTAIN VIEW, Calif., Sept. 7, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that data on its MicroPulse P3 (MP3) device powered by the same proprietary MicroPulse laser technology in the IRIDEX Cyclo G6 glaucoma laser system show long-term benefits for patients with refractory glaucoma. The data were originally presented at the European Glaucoma Society (EGS) Meeting on June 19-22, 2016, in Prague, Czech Republic.

The data, presented by Maria Cecilia Aquino, M.D., and Paul Chew, M.D., and titled 'Long-term Efficacy of MicroPulse Diode Transscleral Cyclophotocoagulation in the Treatment of Refractory Glaucoma,' were the results of retrospective case studies that aimed to evaluate and present the long-term efficacy of MicroPulse transscleral cyclophotocoagulation (MPCPC) in subjects with refractory glaucoma treated from a prior prospective trial concluded in 2014.

'Dr. Aquino and I are thrilled to have successfully followed this cohort of patients over the course of six and a half years to determine the long-term benefits of the MicroPulse technology for patients with refractory glaucoma,' said Dr. Chew, associate professor, National University Hospital and National University, Singapore. 'We can now say with confidence that MicroPulse is not only safe and efficacious for the acute reduction of intraocular pressure (IOP), but is also an excellent option for ophthalmologists looking to provide durable relief to their patients.'

A study population of 14 subjects with refractory glaucoma treated from the initial prospective exploratory study of 23 patients were reviewed. IOP and number of medications on the last review visit were recorded. Success was defined as 30 percent or more final IOP reduction from baseline. Mean pretreatment IOP was 43.3 mmHg (range 22-73) and IOP at last follow-up was 24.8 mmHg (range 12-56).

'These outcomes represent a significant milestone for MicroPulse and IRIDEX, signifying the longest-term data set we have to date for this system,' said President and CEO Will Moore. 'To be able to showcase six and a half years worth of efficacy data and decreased medication loads, even in a small set of patients, is a testament to our mission to provide a safe, non-incisional, repeatable and more cost-effective alternative to treating glaucoma. It should also be noted the patients were treated with the MP3 on average 4 times during the six and a half years.'

About MicroPulse Technology
MicroPulse is a tissue-sparing laser delivery therapy that works by electronically 'chopping' the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company maintains a deep commitment to the success of its customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at www.iridex.com.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, including in relation to the Company's products, including MicroPulse® technology, the usage and efficacy of the Company's products, and the Company's strategic plans and objectives. Actual results could differ materially and adversely from those projected in the forward-looking statements. Please see a detailed description of the Company's risks contained in our Quarterly Reports on Form 10-K for the fiscal year ended January 2, 2016, and our Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Logo - http://photos.prnewswire.com/prnh/20141001/149809

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iridex-announces-long-term-glaucoma-efficacy-data-for-patients-treated-with-micropulse-p3-probe-technology-300323458.html

SOURCE IRIDEX Corporation

IRIDEX Contact; Atabak Mokari; CFO and Vice President, Corporate Development; 650-940-4700 or Investor Contact; Matt Clawson; Pure Communications; 949-370-8500; matt@purecommunicationsinc.com or Media Contact; Julia Baron; Pure Communications; 858-692-2001; julia@purecommunicationsinc.com